OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation
Proceeds provide OMEICOS with the financial runway to conduct the Phase II Study PROMISE-AF and continue expansion into ophthalmology through US subsidiary